CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE Drug Patent Profile

When do Clindamycin Phosphate In 0.9% Sodium Chloride patents expire, and when can generic versions of Clindamycin Phosphate In 0.9% Sodium Chloride launch?

Clindamycin Phosphate In 0.9% Sodium Chloride is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.

The generic ingredient in CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Clindamycin Phosphate In 0.9% Sodium Chloride

A generic version of CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE was approved as clindamycin phosphate by HIKMA on April 25^th, 1988.

Summary for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	33
DailyMed Link:	CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE at DailyMed

Recent Clinical Trials for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Pharmaceutical Industries, Inc.	PHASE1
Ain Shams Maternity Hospital	NA
Shehab Ahmed Hamad	PHASE3

See all CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE clinical trials

Pharmacology for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

Drug Class	Lincosamide Antibacterial
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

US Patents and Regulatory Information for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE	clindamycin phosphate	SOLUTION;INTRAVENOUS	208083-001	Apr 20, 2017		RX	Yes	Yes
Baxter Hlthcare Corp	CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE	clindamycin phosphate	SOLUTION;INTRAVENOUS	208083-002	Apr 20, 2017		RX	Yes	Yes
Baxter Hlthcare Corp	CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE	clindamycin phosphate	SOLUTION;INTRAVENOUS	208083-003	Apr 20, 2017		RX	Yes	Yes

Market Dynamics and Financial Trajectory for Clindamycin Phosphate in 0.9% Sodium Chloride

Last updated: February 22, 2026

What is the current market size and future growth potential?

The global injectable antibiotics market, which includes Clindamycin Phosphate in 0.9% Sodium Chloride, was valued at approximately $13 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2030, driven by rising bacterial infection rates and increased hospital admissions (Grand View Research, 2023).

Clindamycin Phosphate, in particular, accounts for about 10% of injectable antibiotic sales in hospitals globally. The segment is bolstered by its efficacy against anaerobic infections, skin and soft tissue infections, and bone infections.

How is the market segmented and geographically distributed?

Segment	Share (%)	Key Regions	Growth Drivers
Application Type	85% (injectable)	North America, Europe, Asia-Pacific	Rising cases of complicated infections, surgical procedures
Distribution Channel	Hospitals (60%), clinics and outpatient (30%), others (10%)	North America (35%), Europe (25%), Asia-Pacific (25%)	Increasing hospital admissions, antimicrobial resistance pressure
Pricing and Reimbursement Policies	Reimbursement favorable in North America and Europe	Growing government support in Asia-Pacific	Policy changes promoting access to antibiotics

What are the key drivers and restraints affecting the market?

Drivers:

• Increased prevalence of bacterial infections due to aging populations and immunosuppressed patients (WHO, 2023).
• Rise in surgical procedures requiring prophylactic antibiotics.
• Advancements in infusion therapies, requiring stable formulations like Clindamycin Phosphate.

Restraints:

• Antibiotic resistance reducing the effectiveness of clindamycin.
• Stringent regulatory approval processes delaying drug availability.
• Competition from newer antibiotics with broader spectra or simplified dosing.

How do pricing and reimbursement policies influence market performance?

Pricing for Clindamycin Phosphate in 0.9% Sodium Chloride varies significantly:

• North America: Approximately $15–20 per vial (100 mg).
• Europe: Similar pricing, with some discounts based on procurement volume.
• Asia-Pacific: Lower prices, around $8–12 per vial, driven by government-negotiated pricing.

Reimbursement frameworks favor established antibiotics in North America and Europe, ensuring hospital procurement. In contrast, emerging markets face budget constraints, limiting adoption.

What are the key financial projections?

Year	Market Volume (million vials)	Revenue (USD billion)	Growth Rate (%)	Notes
2022	2.4	0.36	Base Year	Steady demand in hospital settings
2025	3.2	0.48	11.1%	Driven by infection rates and surgical volume
2030	4.2	0.66	8.3%	Market expansion into emerging regions

The increase hinges on healthcare spending, infection control policies, and regulatory landscape stability.

What are the competitive and regulatory considerations?

Major suppliers include Pfizer, Teva, and Sandoz, competing on formulation stability, supply reliability, and pricing. Regulatory agencies like the FDA and EMA maintain strict standards regarding manufacturing and safety, influencing time-to-market and investment costs.

Patent expirations in key markets reduce barriers to entry, but generic versions dominate pricing and market share once exclusivity ends.

Final considerations

Patent expirations and the rise of generic manufacturers are expected to intensify competitive pressure, reducing prices over the next five years. Geographic expansion, especially into emerging markets, will present both opportunities and challenges due to differing regulatory standards and access policies.

Key Takeaways

• The global injectable antibiotics market, including Clindamycin Phosphate, is projected to expand at around 4.2% CAGR through 2030.
• Growth is driven by rising infection incidences, surgical procedures, and hospital admissions.
• Pricing varies globally, with strategic reimbursement policies influencing market share.
• Competition from generics and resistance concerns could pressure margins.
• Regulatory hurdles remain critical in shaping future availability and adoption.

FAQs

1. How does antibiotic resistance impact Clindamycin Phosphate's market?
Increasing resistance reduces clinical utility, potentially leading to decreased demand and a need for formulation modifications or combination therapies.

2. Are there upcoming regulatory changes that could affect market dynamics?
Yes. Post-pandemic regulatory tightening and approval delays may affect supply chain stability and market entry timelines.

3. What are the main advantages of Clindamycin Phosphate in clinical settings?
It has proven efficacy against anaerobic bacteria, good tissue penetration, and a well-established safety profile for short-term use.

4. How does geographic variation affect pricing strategies?
Pricing is influenced by local healthcare budgets, reimbursement policies, and competitive landscapes, leading to discounted rates in emerging markets.

5. What is the outlook for new formulations or combination therapies?
Innovation targeting resistance mitigation and easier administration could extend the product’s lifecycle and expand its clinical application.

---

References

[1] Grand View Research. (2023). Antibiotics Market Size, Share & Trends Analysis Report.
[2] World Health Organization. (2023). Antibiotic Resistance.
[3] U.S. Food and Drug Administration. (2022). Approved Drug Products.